August 2nd 2025
In case you missed it, this week we had news about Johnson & Johnson's sBLA for guselkumab structural damage data, insights from LEO Pharma on the recent delgocitinib approval, the FDA's Fast Track designation for rezpegaldesleukin, and more.
Commemorating Dermatology Times’ 45th Anniversary
Explore dermatology's history and the journey through our publication's 45 years of covering an ever evolving specialty.